Answers go deeper than the script: questioning keeps surfacing new concrete detail behind a positive development · compa
The model's full reasoning — Q3 2022 call → NOWe need answer only YES or NO. Need evaluate both gates. Need use only transcript. Gate 1: positive current development, Q&A adds more concrete operating detail than prepared remarks. Need identify development. Prepared remarks: RMC-6236 and RMC-6291 in Phase I/Ib dose escalation, RMC-9805 IND-enabling toward mid-2023, RMC-4630 combo with sotorasib, RMC-5552. Q&A: analysts ask about enrollment pace, 6236 patient interest, 6291 superiority, 9805 PK, 6236 histology/mutation bias, 6291 development path, 6236 expansion, 5552 combinations, competitor comparisons. Do management answers add concrete operating detail? Let's examine. Question 1: 6236 vs mutant selective, 5552 combos. Mark says don't know enough, guesses, "we're in dose escalation, we'll figure out" - not concrete. Steve on 5552: "primary focus... assess whether drug worthy... we have shown ON timely toxicity, PK exposures within range consistent with activity, efficacy. So confident... initial focus co-mutations... plenty preclinical data... RMC-5552 can act favorably in combination... P1 co-mutant GMOs, lung tumors do not do well with single-agent basis." This is somewhat additive about 5552 development rationale, but not current operating detail? It's about strategy, preclinical. Question 2: pace of enrollment. Mark: "both on track with expectations. We expected 6236 abundance of patients and investigators highly interested because absence approved targeted therapies... very high demand for fixed number of stuff... enrollment in both studies per plan." No specific numbers, but confirms demand. Not much new. Question 3: 6291 superior activity. Mark: "as we start to collect data, things we see initially safety/tolerability, then tumor activity, objective responses earliest, durability later. Any combination helpful... big picture G12C space likely combination therapy... moving there... real impact patients combinations... can only come after reach recommended Phase II dose." This is general, no new specifics. Question 4: 9805 PK. Mark: "barely bioavailable across multiple species at percent appropriate... orally available... no difficulty getting above IC50/IC90, relatively long half-life, retained tissues due covalence... behaves very much like RMC-6291 in dose PK/PD efficacy selectivity. Preclinical, surprised if don't carry into people." This is preclinical, not current human development.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| MNDY | monday.com Ltd. | Q4 2024 | 2024-05-15 | A |
| ZLAB | Zai Lab Limited | Q1 2024 | 2024-05-09 | B |
| YOU | Clear Secure, Inc. | Q1 2024 | 2024-05-08 | C+ |
| STIM | Neuronetics, Inc. | Q1 2024 | 2024-05-07 | B |
| CMG | Chipotle Mexican Grill, Inc. | Q1 2024 | 2024-04-24 | A |
| CSGP | CoStar Group, Inc. | Q1 2024 | 2024-04-23 | B+ |
| SAP | SAP SE | Q1 2024 | 2024-04-22 | B |
| AREC | American Resources Corporation | Q4 2023 | 2024-03-28 | F |
| QRHC | Quest Resource Holding Corporation | Q4 2023 | 2024-03-12 | C |
| ALKT | Alkami Technology, Inc. | Q4 2023 | 2024-03-02 | A |
| MCW | Mister Car Wash, Inc. | Q4 2023 | 2024-02-21 | D |
| TYL | Tyler Technologies, Inc. | Q4 2023 | 2024-02-15 | C+ |
| GDDY | GoDaddy Inc. | Q4 2023 | 2024-02-13 | A |
| SYY | Sysco Corporation | Q2 2024 | 2024-01-30 | B+ |
| STLD | Steel Dynamics, Inc. | Q4 2023 | 2024-01-24 | C+ |
| CSPI | CSP Inc. | Q4 2023 | 2023-12-12 | D |
| ATXS | Astria Therapeutics, Inc. | Q3 2023 | 2023-11-13 | C |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| VCEL | Vericel Corporation | Q3 2023 | 2023-11-08 | A |
| SG | Sweetgreen, Inc. | Q3 2023 | 2023-11-04 | D |
| CHRD | Chord Energy Corporation | Q3 2023 | 2023-11-02 | A |
| PLTR | Palantir Technologies Inc. | Q3 2023 | 2023-11-02 | B |
| REGN | Regeneron Pharmaceuticals, Inc. | Q3 2023 | 2023-11-02 | C |
| DASH | DoorDash, Inc. | Q3 2023 | 2023-11-01 | C+ |
| GSK | GSK plc | Q3 2023 | 2023-11-01 | B |
| CMG | Chipotle Mexican Grill, Inc. | Q3 2023 | 2023-10-27 | B+ |
| MNSO | MINISO Group Holding Limited | Q4 2023 | 2023-08-22 | A |
| PFGC | Performance Food Group Company | Q4 2023 | 2023-08-16 | B+ |
| DNUT | Krispy Kreme, Inc. | Q2 2023 | 2023-08-10 | C |
| RBLX | Roblox Corporation | Q2 2023 | 2023-08-09 | C+ |
| PODD | Insulet Corporation | Q2 2023 | 2023-08-08 | B+ |
| MVST | Microvast Holdings, Inc. | Q2 2023 | 2023-08-07 | C |
| PTLO | Portillo's Inc. | Q2 2023 | 2023-08-05 | B |
| CIVI | Civitas Resources, Inc. | Q2 2023 | 2023-08-03 | B |
| IDT | IDT Corporation | Q3 2023 | 2023-06-05 | C |
| STIM | Neuronetics, Inc. | Q1 2023 | 2023-05-13 | B |
| VECO | Veeco Instruments Inc. | Q1 2023 | 2023-05-08 | B |
| LTH | Life Time Group Holdings, Inc. | Q1 2023 | 2023-04-25 | A |
| SCPH | scPharmaceuticals Inc. | Q4 2022 | 2023-03-22 | C+ |
| COCO | The Vita Coco Company, Inc. | Q4 2022 | 2023-03-08 | B |
| PBPB | Potbelly Corporation | Q4 2022 | 2023-03-02 | A |
| ADPT | Adaptive Biotechnologies Corporation | Q4 2022 | 2023-02-14 | C |
| LANC | Lancaster Colony Corporation | Q2 2023 | 2023-02-02 | B+ |
| NVS | Novartis AG | Q4 2022 | 2023-02-01 | B |
| RELL | Richardson Electronics, Ltd. | Q2 2023 | 2023-01-05 | B+ |
| CUTR | Cutera, Inc. | Q3 2022 | 2022-11-05 | C |
| MUR | Murphy Oil Corporation | Q3 2022 | 2022-11-03 | A |
| LPX | Louisiana-Pacific Corporation | Q3 2022 | 2022-11-01 | B+ |
| INMD | InMode Ltd. | Q3 2022 | 2022-10-27 | A |
| INVZ | Innoviz Technologies Ltd | Q2 2022 | 2022-08-10 | D |
| FLGT | Fulgent Genetics, Inc. | Q2 2022 | 2022-08-04 | C+ |
| GTHX | G1 Therapeutics, Inc. | Q1 2022 | 2022-08-03 | D |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| TMUS | T-Mobile US, Inc. | Q2 2022 | 2022-07-27 | B+ |
| AZO | AutoZone, Inc. | Q3 2022 | 2022-05-24 | A |
| AXON | Axon Enterprise, Inc. | Q1 2022 | 2022-05-10 | B+ |
| VEV | Vicinity Motor Corp. | Q4 2021 | 2022-03-30 | D |
| HRTX | Heron Therapeutics, Inc. | Q4 2021 | 2022-02-28 | D |
| INCY | Incyte Corporation | Q4 2021 | 2022-02-08 | C+ |
| TMDX | TransMedics Group, Inc. | Q3 2021 | 2021-11-09 | C+ |
| ATRC | AtriCure, Inc. | Q3 2021 | 2021-11-03 | C |
| SUPN | Supernus Pharmaceuticals, Inc. | Q3 2021 | 2021-11-03 | C |
| ZI | ZoomInfo Technologies Inc. | Q3 2021 | 2021-11-01 | A |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| CHWY | Chewy, Inc. | Q2 2021 | 2021-09-01 | B |
| VVV | Valvoline Inc. | Q3 2021 | 2021-08-06 | A |
| TIGO | Millicom International Cellular S.A. | Q2 2021 | 2021-07-31 | B+ |
| SAP | SAP SE | Q2 2021 | 2021-07-21 | B+ |
| UPWK | Upwork Inc. | Q3 2018 | 2018-11-11 | B+ |
| MYO | Myomo, Inc. | Q3 2018 | 2018-11-05 | C |
| CFG | Citizens Financial Group, Inc. | Q3 2018 | 2018-10-19 | A |
| UAL | United Airlines Holdings, Inc. | Q3 2018 | 2018-10-17 | B+ |
| INSP | Inspire Medical Systems, Inc. | Q2 2018 | 2018-08-12 | A |
| REI | Ring Energy, Inc. | Q2 2018 | 2018-08-09 | B |
| GAIA | Gaia, Inc. | Q2 2018 | 2018-08-06 | A |
| RNG | RingCentral, Inc. | Q2 2018 | 2018-08-06 | A |
| FRPT | Freshpet, Inc. | Q2 2018 | 2018-08-06 | B+ |
| TSLA | Tesla, Inc. | Q2 2018 | 2018-08-02 | B |
| OOMA | Ooma, Inc. | Q1 2019 | 2018-05-22 | A |
| ZG | Zillow Group's | Q1 2018 | 2018-05-08 | C+ |
| QLYS | Qualys, Inc. | Q1 2018 | 2018-05-02 | A |
| CPS | Cooper-Standard Holdings Inc. | Q1 2018 | 2018-05-02 | B |
| VRTX | Vertex Pharmaceuticals Incorporated | Q1 2018 | 2018-04-26 | C+ |
| SYK | Stryker Corporation | Q1 2018 | 2018-04-26 | B+ |
| TNC | Tennant Company | Q4 2017 | 2018-02-22 | B |
| TMUS | T-Mobile US, Inc. | Q4 2017 | 2018-02-09 | B+ |
| NICE | NICE Ltd. | Q3 2017 | 2017-11-04 | A |
| SAMG | Silvercrest Asset Management Group Inc. | Q3 2017 | 2017-11-03 | A |
| VC | Visteon Corporation | Q3 2017 | 2017-10-28 | B+ |
| PRO | PROS Holdings, Inc. | Q3 2017 | 2017-10-26 | A |
| SRPT | Sarepta Therapeutics, Inc. | Q3 2017 | 2017-10-26 | C+ |
| CAL | Caleres, Inc. | Q2 2017 | 2017-08-29 | B+ |
| LITE | Lumentum Holdings Inc. | Q4 2017 | 2017-08-09 | B+ |
| FRPT | Freshpet, Inc. | Q2 2017 | 2017-08-07 | B+ |
| INTU | Intuit Inc. | Q3 2017 | 2017-05-23 | A |
| ADAP | Adaptimmune Therapeutics plc | Q1 2017 | 2017-05-10 | D |
| ISDR | Issuer Direct Corporation | Q1 2017 | 2017-05-06 | C |
| XPO | XPO Logistics, Inc. | Q1 2017 | 2017-05-04 | B |
| SRPT | Sarepta Therapeutics, Inc. | Q1 2017 | 2017-04-28 | D |
| SAH | Sonic Automotive, Inc. | Q1 2017 | 2017-04-26 | C |
| SYK | Stryker Corporation | Q4 2016 | 2017-01-24 | C+ |
| MCS | The Marcus Corporation | Q3 2016 | 2016-10-27 | C+ |
| GSK | GSK plc | Q3 2016 | 2016-10-26 | B |
| VYGR | Voyager Therapeutics, Inc. | Q2 2016 | 2016-08-11 | A |
| SQ | Square's | Q2 2016 | 2016-08-04 | A |
| DGII | Digi International Inc. | Q3 2016 | 2016-07-28 | B |
| PAR | PAR Technology Corporation | Q1 2016 | 2016-05-04 | D |
| PM | Philip Morris International Inc. | Q1 2016 | 2016-04-19 | B+ |
RBLX · Q2 2023 → YESThe task is to evaluate two gates based on the earnings call transcript and return YES only if both are YES, otherwise NO. YES The transcript shows a clear positive current development in advertising, where management's prepared remarks mention live ads, 200 activations, 19% of top 100 with ad units, and some demand exceeding supply. In the Q&A, they add fresh specifics like pricing strategy (gentle now, floating later), new ad unit types, 12% of top 100 using portals, demand in 17-24 female cohort, self-serve options, and brand volume challenges. These details are operational and additive across multiple exchanges, meeting GATE 1 criteria. For GATE 2, advertising is driven by Roblox's own creation and control: 200 activations, portal ad units, self-serve platform, and rollout execution. It's not reliant on external industry tailwinds but on their platform improvements and brand engagement. This satisfies the primary engine condition.
SG · Q3 2023 → YESThe task is to evaluate two gates based on the Sweetgreen earnings call transcript and return YES only if both gates are YES, otherwise NO. YES The transcript shows a clear positive current development in Infinite Kitchen, with management's Q&A responses adding substantial new operational details—such as first-unit performance, customer experience improvements, margin leverage, AUV targeting, retrofit opportunities, and throughput optimizations—that go beyond the prepared remarks' high-level plans. This satisfies Gate 1 criteria for additive, substantive detail across multiple exchanges. For Gate 2, Infinite Kitchen is a proprietary technology the company developed and controls, with momentum driven by its own execution, customer adoption, and operational refinements rather than external tailwinds, making it the primary engine.
ALKT · Q4 2023 → YESThe task is to evaluate two gates based on the earnings call transcript and return YES only if both are YES, otherwise NO. YES The transcript shows a clear positive current development in the bank's market progress and add-on sales momentum, with Q&A providing substantial new operational details like specific backlog numbers, implementation timelines, product adoption rates, and customer-specific challenges that go beyond the prepared remarks. For GATE 2, the primary engine is Alkami's own platform, cloud-native architecture, and execution on replacements of legacy systems, which would largely continue even if external conditions shifted, as the company is actively winning share through its controlled rollout and product improvements.